493 related articles for article (PubMed ID: 33287402)
1. Galectin-3 in Cardiovascular Diseases.
Blanda V; Bracale UM; Di Taranto MD; Fortunato G
Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33287402
[TBL] [Abstract][Full Text] [Related]
2. Research progress on the role of gal-3 in cardio/cerebrovascular diseases.
Cao ZQ; Yu X; Leng P
Biomed Pharmacother; 2021 Jan; 133():111066. PubMed ID: 33378967
[TBL] [Abstract][Full Text] [Related]
3. In silico-based Approach to Investigate the Ability of PEGylated Rapamycin to Inhibit Galectin-3.
Abdelkarim Maki MA; Kumar PV; Elumalai M; Bayazeid O
Curr Drug Discov Technol; 2021; 18(3):451-456. PubMed ID: 31969105
[TBL] [Abstract][Full Text] [Related]
4. The emerging role of galectins in cardiovascular disease.
van der Hoeven NW; Hollander MR; Yıldırım C; Jansen MF; Teunissen PF; Horrevoets AJ; van der Pouw Kraan TC; van Royen N
Vascul Pharmacol; 2016 Jun; 81():31-41. PubMed ID: 26945624
[TBL] [Abstract][Full Text] [Related]
5. Molecular mechanism of interspecies differences in the binding affinity of TD139 to Galectin-3.
Kumar A; Paul M; Panda M; Jayaram S; Kalidindi N; Sale H; Vetrichelvan M; Gupta A; Mathur A; Beno B; Regueiro-Ren A; Cheng D; Ramarao M; Ghosh K
Glycobiology; 2021 Nov; 31(10):1390-1400. PubMed ID: 34228782
[TBL] [Abstract][Full Text] [Related]
6. The therapeutic potential of galectin-3 inhibition in fibrotic disease.
Slack RJ; Mills R; Mackinnon AC
Int J Biochem Cell Biol; 2021 Jan; 130():105881. PubMed ID: 33181315
[TBL] [Abstract][Full Text] [Related]
7. Galectin-9 as a biomarker of disease severity.
Moar P; Tandon R
Cell Immunol; 2021 Mar; 361():104287. PubMed ID: 33494007
[TBL] [Abstract][Full Text] [Related]
8. Plasma and Cardiac Galectin-3 in Patients With Heart Failure Reflects Both Inflammation and Fibrosis: Implications for Its Use as a Biomarker.
Besler C; Lang D; Urban D; Rommel KP; von Roeder M; Fengler K; Blazek S; Kandolf R; Klingel K; Thiele H; Linke A; Schuler G; Adams V; Lurz P
Circ Heart Fail; 2017 Mar; 10(3):. PubMed ID: 28288987
[TBL] [Abstract][Full Text] [Related]
9. Galectin-3 in prostate cancer and heart diseases: a biomarker for these two frightening pathologies?
Lima T; Perpétuo L; Henrique R; Fardilha M; Leite-Moreira A; Bastos J; Vitorino R
Mol Biol Rep; 2023 Mar; 50(3):2763-2778. PubMed ID: 36583779
[TBL] [Abstract][Full Text] [Related]
10. Possible value of galectin-3 on follow-up of cardiac remodeling during glucocorticoid treatment.
Akin S; Kubat GB; Guray U; Akin Y; Demirel HA
J Biochem Mol Toxicol; 2021 Apr; 35(4):e22717. PubMed ID: 33484019
[TBL] [Abstract][Full Text] [Related]
11. Galectin-3 and acute heart failure: genetic polymorphisms, plasma level, myocardial fibrosis and 1-year outcomes.
Fu H; Nie S; Luo P; Ruan Y; Zhang Z; Miao H; Li X; Wen S; Bai R
Biomark Med; 2020 Jul; 14(11):943-954. PubMed ID: 32940080
[No Abstract] [Full Text] [Related]
12. The Role of Galectin-3 in Heart Failure-The Diagnostic, Prognostic and Therapeutic Potential-Where Do We Stand?
Zaborska B; Sikora-Frąc M; Smarż K; Pilichowska-Paszkiet E; Budaj A; Sitkiewicz D; Sygitowicz G
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37685918
[TBL] [Abstract][Full Text] [Related]
13. Review of galectin-3 inhibitors in the treatment of nonalcoholic steatohepatitis.
Al Attar A; Antaramian A; Noureddin M
Expert Rev Clin Pharmacol; 2021 Apr; 14(4):457-464. PubMed ID: 33612037
[TBL] [Abstract][Full Text] [Related]
14. Role of galectin-3 in autoimmune and non-autoimmune nephropathies.
Saccon F; Gatto M; Ghirardello A; Iaccarino L; Punzi L; Doria A
Autoimmun Rev; 2017 Jan; 16(1):34-47. PubMed ID: 27666815
[TBL] [Abstract][Full Text] [Related]
15. Cardiac-deleterious role of galectin-3 in chronic angiotensin II-induced hypertension.
González GE; Rhaleb NE; D'Ambrosio MA; Nakagawa P; Liao TD; Peterson EL; Leung P; Dai X; Janic B; Liu YH; Yang XP; Carretero OA
Am J Physiol Heart Circ Physiol; 2016 Nov; 311(5):H1287-H1296. PubMed ID: 27496875
[TBL] [Abstract][Full Text] [Related]
16. Galectin-3 as a Next-Generation Biomarker for Detecting Early Stage of Various Diseases.
Hara A; Niwa M; Noguchi K; Kanayama T; Niwa A; Matsuo M; Hatano Y; Tomita H
Biomolecules; 2020 Mar; 10(3):. PubMed ID: 32138174
[TBL] [Abstract][Full Text] [Related]
17. CT-1 (Cardiotrophin-1)-Gal-3 (Galectin-3) Axis in Cardiac Fibrosis and Inflammation.
Martínez-Martínez E; Brugnolaro C; Ibarrola J; Ravassa S; Buonafine M; López B; Fernández-Celis A; Querejeta R; Santamaria E; Fernández-Irigoyen J; Rábago G; Moreno MU; Jaisser F; Díez J; González A; López-Andrés N
Hypertension; 2019 Mar; 73(3):602-611. PubMed ID: 30612490
[TBL] [Abstract][Full Text] [Related]
18. Galectins-A Potential Target for Cardiovascular Therapy.
Ashraf GM; Perveen A; Zaidi SK; Ahmad A; Shakil S; Firoz CK; Jabir NR; Hassan I; Khan TA; Yarla NS; Tabrez S
Curr Vasc Pharmacol; 2017; 15(4):296-312. PubMed ID: 28155611
[TBL] [Abstract][Full Text] [Related]
19. Galectin-3: A factotum in carcinogenesis bestowing an archery for prevention.
Jeethy Ram T; Lekshmi A; Somanathan T; Sujathan K
Tumour Biol; 2021; 43(1):77-96. PubMed ID: 33998569
[TBL] [Abstract][Full Text] [Related]
20. Galectin-3 Is a Potential Mediator for Atherosclerosis.
Gao Z; Liu Z; Wang R; Zheng Y; Li H; Yang L
J Immunol Res; 2020; 2020():5284728. PubMed ID: 32149158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
